{"gene":"NOG","run_date":"2026-04-29T11:37:57","timeline":{"discoveries":[{"year":2001,"finding":"Disease-causing NOG missense mutations (one SYNS1 and two SYM1) reduce or abolish secretion of functional noggin dimers in transiently transfected COS-7 cells; coexpression of mutant with wild-type noggin does not interfere with wild-type secretion, indicating hypomorphic alleles that reduce functional dimeric noggin secretion. Species-specific differences were also noted: the SYNS1 mutant could still form dimers in Xenopus laevis oocytes but not in COS-7 cells.","method":"Transient transfection in COS-7 cells, dimer formation assay, BMP binding assay, Xenopus oocyte expression","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro functional assay with multiple mutant alleles, BMP-binding and dimerization readouts, cross-species validation","pmids":["11562478"],"is_preprint":false},{"year":2002,"finding":"Heterozygous nonsense (Q110X) and frameshift (c.252-253insC) NOG mutations predicted to truncate or disrupt the cysteine-rich C-terminal domain cause a congenital stapes ankylosis syndrome distinct from SYM1/SYNS1, establishing that the C-terminal cysteine-rich domain is critical for noggin function and that different truncating mutations produce different skeletal phenotypes.","method":"Sequencing of NOG in affected families; genotype-phenotype correlation","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 3 — genetic identification of loss-of-function alleles with clear functional inference about domain requirement, but no direct in vitro functional assay","pmids":["12089654"],"is_preprint":false},{"year":2001,"finding":"Identical NOG missense mutations (e.g., those originally described in SYM1) can also cause tarsal/carpal coalition syndrome (TCC), demonstrating that the same NOG allele can produce different skeletal fusion phenotypes, implying epistatic modifiers act on the NOG pathway.","method":"Genetic sequencing of NOG in three kindreds with TCC; comparison with known SYM1 mutations","journal":"Genetics in medicine : official journal of the American College of Medical Genetics","confidence":"Medium","confidence_rationale":"Tier 3 + Strong — replicated across multiple families and cross-referenced to prior SYM1 mutations, establishing pathway epistasis context","pmids":["11545688"],"is_preprint":false},{"year":2012,"finding":"NOG (noggin, a BMP inhibitor) expression is selectively acquired by breast cancer cells during bone metastasis (not enriched in primary tumors). Using genetic knockdown/overexpression, NOG was shown to facilitate bone colonization by fostering osteoclast differentiation and bone degradation, and to contribute to metastatic lesion reinitiation, coupling cancer cell-autonomous and nonautonomous (osteoclast-mediated) functions.","method":"Genetic knockdown and overexpression in human breast cancer cells; in vivo bone metastasis assay; osteoclast differentiation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — clean genetic loss-of-function and gain-of-function with defined cellular and in vivo phenotypes (osteoclast differentiation, bone colonization)","pmids":["22547073"],"is_preprint":false},{"year":2022,"finding":"HIF-1α directly binds to a hypoxia response element (HRE at -1505 to -1502) in the NOG promoter to transcriptionally upregulate NOG/Noggin expression under hypoxia, resulting in inhibition of osteogenic differentiation of periodontal ligament stem cells (PDLSCs). Overexpression of HIF-1α increased Noggin levels and suppressed osteogenesis-related gene expression; HIF-1α inhibition reversed these effects.","method":"Chromatin immunoprecipitation (ChIP), dual-luciferase reporter assay, qRT-PCR, Western blot, HIF-1α overexpression/inhibition in PDLSCs, in vivo animal model IHC","journal":"Experimental cell research","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP and luciferase reporter directly demonstrate HIF-1α binding to NOG promoter HRE; supported by gain/loss-of-function experiments and in vivo validation","pmids":["36002046"],"is_preprint":false},{"year":2014,"finding":"Myo/Nog cells in the chick embryo express both MyoD mRNA and the BMP inhibitor Noggin (Nog). Ablation of Myo/Nog cells in the blastocyst expands canonical BMP signaling, prevents noggin and follistatin expression before and after gastrulation, and causes severe axial malformations with loss of skeletal muscle progenitors (Pax3+); reintroduction of Myo/Nog cells restores normal BMP signaling, morphogenesis, and skeletal myogenesis. This identifies Myo/Nog cells as essential regulators of BMP signaling in the early epiblast through Noggin secretion.","method":"Cell ablation in chick blastocyst using G8 mAb + complement; reintroduction rescue experiments; immunofluorescence for BMP pathway components and myogenic markers","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 — ablation with rescue, multiple orthogonal readouts (BMP signaling, Pax3 expression, myogenesis markers), establishes NOG's role in BMP inhibition in developmental context","pmids":["21884693"],"is_preprint":false},{"year":2014,"finding":"Myo/Nog cells are the primary source of noggin in telogen hair follicles and in anterior lens tissue. Depletion of Myo/Nog cells from human lens explants eliminated cells expressing skeletal muscle proteins (including vimentin, MyoD, sarcomeric myosin) without affecting differentiating lens epithelial cells, and prevented TGF-β-induced skeletal muscle protein expression, demonstrating that Myo/Nog cells are the source of myofibroblast precursors in the lens and that Noggin from these cells modulates BMP signaling in lens tissue.","method":"G8 antibody-mediated depletion of Myo/Nog cells from human lens explants; immunofluorescence; TGF-β stimulation assay","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2-3 — depletion experiment with clear phenotypic readout in human tissue; single lab","pmids":["24736495"],"is_preprint":false},{"year":2021,"finding":"A 30 bp deletion at a splice site in the NOG gene in Boxer dogs is significantly associated with spontaneous superficial chronic corneal epithelial defects (SCCEDs). NOG deletion dogs showed reduced NOG, BMP4, MMP13, and NCAM1 expression and increased BMP2 by IHC, indicating that constitutive NOG expression in the cornea inhibits BMP signaling to regulate limbal epithelial progenitor cells (LEPC), and loss of NOG dysregulates LEPC, contributing to corneal epithelial defects.","method":"Whole genome sequencing; RNA sequencing of corneal tissue; immunohistochemistry of corneal sections","journal":"BMC veterinary research","confidence":"Medium","confidence_rationale":"Tier 2-3 — natural loss-of-function model with transcriptomic and IHC validation; functional link to BMP pathway supported by multi-gene expression data","pmids":["34311726"],"is_preprint":false},{"year":2015,"finding":"A common variant (rs227727) near NOG disrupts enhancer activity in vitro, and a significant cluster of non-coding rare variants near NOG were identified in orofacial cleft patients, suggesting that cis-regulatory elements controlling NOG expression are functional contributors to cleft risk.","method":"Targeted sequencing in 1,409 trios; enhancer activity assay in vitro","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2-3 — functional enhancer assay with statistical genetic support; limited to one in vitro readout for NOG-specific variant","pmids":["25704602"],"is_preprint":false}],"current_model":"NOG encodes Noggin, a secreted BMP antagonist that forms functional dimers via its cysteine-rich C-terminal domain; disease-causing missense mutations reduce or abolish functional dimer secretion (hypomorphic alleles), while truncating mutations in the C-terminal domain produce distinct skeletal fusion phenotypes. Noggin inhibits BMP signaling in skeletal and epithelial development (regulating joint formation, bone remodeling, and limbal progenitor maintenance), is transcriptionally upregulated by HIF-1α binding directly to a promoter HRE under hypoxia, and in cancer facilitates bone metastasis colonization by promoting osteoclast differentiation and bone degradation."},"narrative":{"teleology":[{"year":2001,"claim":"Establishing how disease-causing NOG mutations impair protein function resolved the molecular basis of symphalangism/synostosis: missense alleles are hypomorphic because they reduce or abolish secretion of functional noggin dimers without dominant-negative interference with wild-type protein.","evidence":"Transient transfection of mutant and wild-type NOG in COS-7 cells with dimer formation and BMP-binding assays; cross-species validation in Xenopus oocytes","pmids":["11562478"],"confidence":"High","gaps":["Crystal structure of mutant dimers was not resolved","Cell-type specificity of dimerization failure (COS-7 vs. Xenopus) was unexplained mechanistically","No in vivo rescue of skeletal phenotype attempted"]},{"year":2001,"claim":"Demonstrating that identical NOG missense mutations produce distinct skeletal fusion phenotypes (SYM1 vs. tarsal/carpal coalition) established that epistatic modifiers act on the NOG/BMP pathway to determine phenotypic outcome.","evidence":"Genetic sequencing of NOG in three TCC kindreds identifying previously reported SYM1 mutations","pmids":["11545688"],"confidence":"Medium","gaps":["Identity of epistatic modifier loci was not determined","No functional assay performed for the TCC-associated alleles in this study"]},{"year":2002,"claim":"Identifying truncating NOG mutations (Q110X and frameshift) that disrupt the cysteine-rich C-terminal domain in a stapes ankylosis phenotype distinct from SYM1/SYNS1 established that the C-terminal domain is essential for noggin function and that allelic heterogeneity at NOG produces a broad phenotypic spectrum.","evidence":"Sequencing of NOG in affected families with congenital stapes ankylosis; genotype-phenotype correlation","pmids":["12089654"],"confidence":"Medium","gaps":["No direct biochemical assay of truncated protein function","Mechanism by which partial C-terminal loss produces stapes-specific ankylosis rather than generalized synostosis was not explained"]},{"year":2012,"claim":"Showing that breast cancer cells selectively acquire NOG expression during bone metastasis and that NOG promotes osteoclast differentiation and bone colonization revealed a non-developmental, pathological role for Noggin's BMP-antagonist activity in the metastatic niche.","evidence":"Genetic knockdown and overexpression in human breast cancer cells; in vivo bone metastasis and osteoclast differentiation assays","pmids":["22547073"],"confidence":"High","gaps":["Which specific BMPs are antagonized in the bone metastatic niche was not identified","Whether NOG's pro-metastatic role extends beyond breast cancer was not tested"]},{"year":2014,"claim":"Ablation and rescue of Myo/Nog cells in chick embryos demonstrated that these cells are essential sources of Noggin that restrain BMP signaling in the epiblast, and that loss of Noggin causes severe axial malformations and loss of skeletal muscle progenitors.","evidence":"G8 mAb + complement-mediated cell ablation in chick blastocyst with reintroduction rescue; immunofluorescence for BMP pathway and myogenic markers","pmids":["21884693"],"confidence":"High","gaps":["Relative contribution of Noggin versus Follistatin from Myo/Nog cells was not separated","Mammalian equivalence of the Myo/Nog cell population was not demonstrated"]},{"year":2014,"claim":"Depletion of Myo/Nog cells from human lens explants identified these cells as the primary Noggin source in lens tissue and as the precursors of TGF-β-induced myofibroblasts, connecting Noggin-mediated BMP inhibition to lens epithelial homeostasis.","evidence":"G8 antibody-mediated depletion from human lens explants; immunofluorescence; TGF-β stimulation","pmids":["24736495"],"confidence":"Medium","gaps":["Single-lab finding not independently replicated","Direct measurement of secreted Noggin levels after depletion was not reported"]},{"year":2015,"claim":"Identifying a common variant near NOG that disrupts enhancer activity and rare non-coding variant clusters in orofacial cleft patients established that cis-regulatory control of NOG expression contributes to craniofacial morphogenesis.","evidence":"Targeted sequencing in 1,409 trios; in vitro enhancer activity assay","pmids":["25704602"],"confidence":"Medium","gaps":["Only one variant tested functionally; remaining rare variants lack individual functional validation","In vivo enhancer activity not confirmed"]},{"year":2021,"claim":"A natural NOG loss-of-function model in dogs showed that constitutive corneal NOG expression inhibits BMP signaling to maintain limbal epithelial progenitor cells, and its loss dysregulates BMP2/BMP4 balance leading to chronic corneal defects.","evidence":"Whole genome sequencing and RNA-seq of corneal tissue in Boxer dogs with 30 bp NOG deletion; IHC validation","pmids":["34311726"],"confidence":"Medium","gaps":["Causal rescue experiment not performed","Whether NOG loss directly or indirectly alters limbal progenitor self-renewal was not resolved"]},{"year":2022,"claim":"Demonstrating that HIF-1α directly binds a hypoxia response element in the NOG promoter to upregulate transcription identified the first direct transcriptional regulator of NOG and linked hypoxia signaling to suppression of osteogenic differentiation via the NOG/BMP axis.","evidence":"ChIP, dual-luciferase reporter assay, HIF-1α overexpression/inhibition in PDLSCs, in vivo IHC","pmids":["36002046"],"confidence":"High","gaps":["Whether HIF-1α regulation of NOG operates in tissues beyond periodontal ligament was not tested","Additional transcription factors controlling NOG in skeletal development remain unidentified"]},{"year":null,"claim":"The structural basis of Noggin dimerization-dependent BMP sequestration at atomic resolution, the full repertoire of transcriptional regulators driving tissue-specific NOG expression, and the identity of epistatic modifiers that determine phenotypic outcome of NOG mutations remain unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution structure of disease-associated Noggin mutant dimers","Epistatic modifier loci for NOG-related skeletal phenotypes not mapped","Comprehensive cis-regulatory map of the NOG locus across tissues not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,3,5]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,3,5,6]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,3,5,7]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[1,2,5,8]}],"complexes":[],"partners":["HIF1A","BMP2","BMP4"],"other_free_text":[]},"mechanistic_narrative":"NOG encodes Noggin, a secreted BMP antagonist that functions as a disulfide-linked homodimer through its cysteine-rich C-terminal domain to inhibit BMP signaling during skeletal, epithelial, and axial development [PMID:11562478, PMID:21884693]. Noggin secretion by specialized Myo/Nog cells is essential for restraining canonical BMP signaling in the early epiblast, hair follicles, lens tissue, and corneal limbal epithelium, where it maintains progenitor cell populations and regulates osteogenic and myogenic differentiation [PMID:21884693, PMID:24736495, PMID:34311726]. Heterozygous loss-of-function mutations in NOG—including missense alleles that abolish functional dimer secretion and truncating mutations disrupting the C-terminal domain—cause a spectrum of skeletal fusion disorders including proximal symphalangism, multiple synostoses syndrome, stapes ankylosis, and tarsal/carpal coalition syndrome, with phenotypic variability implicating epistatic modifiers [PMID:11562478, PMID:12089654, PMID:11545688]. NOG transcription is directly upregulated by HIF-1α binding to a promoter hypoxia response element, and aberrant NOG expression by metastatic breast cancer cells promotes bone colonization by driving osteoclast differentiation and bone degradation [PMID:36002046, PMID:22547073]."},"prefetch_data":{"uniprot":{"accession":"Q13253","full_name":"Noggin","aliases":[],"length_aa":232,"mass_kda":25.8,"function":"Inhibitor of bone morphogenetic proteins (BMP) signaling which is required for growth and patterning of the neural tube and somite. Essential for cartilage morphogenesis and joint formation. Inhibits chondrocyte differentiation through its interaction with GDF5 and, probably, GDF6 (PubMed:21976273, PubMed:26643732)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q13253/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NOG","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NOG","total_profiled":1310},"omim":[{"mim_id":"619034","title":"RNA-BINDING PROTEIN, mRNA-PROCESSING FACTOR, 2; RBPMS2","url":"https://www.omim.org/entry/619034"},{"mim_id":"615589","title":"OTOSCLEROSIS 10; OTSC10","url":"https://www.omim.org/entry/615589"},{"mim_id":"615298","title":"SYMPHALANGISM, PROXIMAL, 1B; SYM1B","url":"https://www.omim.org/entry/615298"},{"mim_id":"612985","title":"IROQUOIS HOMEOBOX PROTEIN 3; IRX3","url":"https://www.omim.org/entry/612985"},{"mim_id":"612839","title":"TET METHYLCYTOSINE DIOXYGENASE 2; TET2","url":"https://www.omim.org/entry/612839"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"brain","ntpm":5.5},{"tissue":"placenta","ntpm":10.0}],"url":"https://www.proteinatlas.org/search/NOG"},"hgnc":{"alias_symbol":[],"prev_symbol":["SYNS1","SYM1"]},"alphafold":{"accession":"Q13253","domains":[{"cath_id":"2.10.90.10","chopping":"48-83_157-232","consensus_level":"medium","plddt":94.973,"start":48,"end":232},{"cath_id":"-","chopping":"113-125_133-153","consensus_level":"medium","plddt":89.0724,"start":113,"end":153}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13253","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13253-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13253-F1-predicted_aligned_error_v6.png","plddt_mean":86.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NOG","jax_strain_url":"https://www.jax.org/strain/search?query=NOG"},"sequence":{"accession":"Q13253","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13253.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13253/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13253"}},"corpus_meta":[{"pmid":"21238430","id":"PMC_21238430","title":"The reconstituted 'humanized liver' in TK-NOG mice is mature and functional.","date":"2011","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/21238430","citation_count":259,"is_preprint":false},{"pmid":"19515798","id":"PMC_19515798","title":"The analysis of the functions of human B and T cells in humanized NOD/shi-scid/gammac(null) (NOG) mice (hu-HSC NOG mice).","date":"2009","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19515798","citation_count":174,"is_preprint":false},{"pmid":"25704602","id":"PMC_25704602","title":"Identification of functional variants for cleft lip with or without cleft palate in or near PAX7, FGFR2, and NOG by targeted sequencing of GWAS loci.","date":"2015","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25704602","citation_count":133,"is_preprint":false},{"pmid":"19502956","id":"PMC_19502956","title":"Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice.","date":"2009","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/19502956","citation_count":114,"is_preprint":false},{"pmid":"18481452","id":"PMC_18481452","title":"NOD/Shi-scid IL2rgamma(null) (NOG) mice more appropriate for humanized mouse models.","date":"2008","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18481452","citation_count":104,"is_preprint":false},{"pmid":"12962725","id":"PMC_12962725","title":"Functional CD5+ B cells develop predominantly in the spleen of NOD/SCID/gammac(null) (NOG) mice transplanted either with human umbilical cord blood, bone marrow, or mobilized peripheral blood CD34+ cells.","date":"2003","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/12962725","citation_count":85,"is_preprint":false},{"pmid":"27458246","id":"PMC_27458246","title":"Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse.","date":"2016","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/27458246","citation_count":81,"is_preprint":false},{"pmid":"12089654","id":"PMC_12089654","title":"Autosomal dominant stapes ankylosis with broad thumbs and toes, hyperopia, and skeletal anomalies is caused by heterozygous nonsense and frameshift mutations in NOG, the gene encoding noggin.","date":"2002","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12089654","citation_count":81,"is_preprint":false},{"pmid":"11562478","id":"PMC_11562478","title":"Human disease-causing NOG missense mutations: effects on noggin secretion, dimer formation, and bone morphogenetic protein binding.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11562478","citation_count":74,"is_preprint":false},{"pmid":"24140055","id":"PMC_24140055","title":"A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections.","date":"2013","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/24140055","citation_count":73,"is_preprint":false},{"pmid":"11846737","id":"PMC_11846737","title":"Mutations of the NOG gene in individuals with proximal symphalangism and multiple synostosis syndrome.","date":"2001","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11846737","citation_count":69,"is_preprint":false},{"pmid":"20666386","id":"PMC_20666386","title":"Bioinspired heme, heme/nonheme diiron, heme/copper, and inorganic NOx chemistry: *NO((g)) oxidation, peroxynitrite-metal chemistry, and *NO((g)) reductive coupling.","date":"2010","source":"Inorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20666386","citation_count":69,"is_preprint":false},{"pmid":"20042463","id":"PMC_20042463","title":"Sym1, the yeast ortholog of the MPV17 human disease protein, is a stress-induced bioenergetic and morphogenetic mitochondrial modulator.","date":"2009","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20042463","citation_count":64,"is_preprint":false},{"pmid":"11545688","id":"PMC_11545688","title":"Identical mutations in NOG can cause either tarsal/carpal coalition syndrome or proximal symphalangism.","date":"2001","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11545688","citation_count":60,"is_preprint":false},{"pmid":"21538686","id":"PMC_21538686","title":"A comprehensive review of reported heritable noggin-associated syndromes and proposed clinical utility of one broadly inclusive diagnostic term: NOG-related-symphalangism spectrum disorder (NOG-SSD).","date":"2011","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/21538686","citation_count":59,"is_preprint":false},{"pmid":"22547073","id":"PMC_22547073","title":"Identification of NOG as a specific breast cancer bone metastasis-supporting gene.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22547073","citation_count":59,"is_preprint":false},{"pmid":"17786304","id":"PMC_17786304","title":"Identification of a key molecular regulator of liver metastasis in human pancreatic carcinoma using a novel quantitative model of metastasis in NOD/SCID/gammacnull (NOG) mice.","date":"2007","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17786304","citation_count":59,"is_preprint":false},{"pmid":"14684154","id":"PMC_14684154","title":"Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice.","date":"2004","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/14684154","citation_count":59,"is_preprint":false},{"pmid":"29151581","id":"PMC_29151581","title":"Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses.","date":"2017","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29151581","citation_count":57,"is_preprint":false},{"pmid":"24200850","id":"PMC_24200850","title":"Human hepatocytes and hematolymphoid dual reconstitution in treosulfan-conditioned uPA-NOG mice.","date":"2013","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24200850","citation_count":56,"is_preprint":false},{"pmid":"25712215","id":"PMC_25712215","title":"Predominant development of mature and functional human NK cells in a novel human IL-2-producing transgenic NOG mouse.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25712215","citation_count":55,"is_preprint":false},{"pmid":"29222435","id":"PMC_29222435","title":"Long-term maintenance of peripheral blood derived human NK cells in a novel human IL-15- transgenic NOG mouse.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29222435","citation_count":55,"is_preprint":false},{"pmid":"1420154","id":"PMC_1420154","title":"Biochemical characterization and electron-transfer reactions of sym1, a Rhodobacter capsulatus reaction center symmetry mutant which affects the initial electron donor.","date":"1992","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1420154","citation_count":54,"is_preprint":false},{"pmid":"23034331","id":"PMC_23034331","title":"CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model.","date":"2012","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/23034331","citation_count":52,"is_preprint":false},{"pmid":"27862942","id":"PMC_27862942","title":"A Novel Xenogeneic Graft-Versus-Host Disease Model for Investigating the Pathological Role of Human CD4+ or CD8+ T Cells Using Immunodeficient NOG Mice.","date":"2016","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/27862942","citation_count":50,"is_preprint":false},{"pmid":"25963555","id":"PMC_25963555","title":"Establishment of patient-derived cancer xenografts in immunodeficient NOG mice.","date":"2015","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25963555","citation_count":47,"is_preprint":false},{"pmid":"17696196","id":"PMC_17696196","title":"FGFR1 over-expression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5' CpG island and abnormal expression of the AKT1, NOG, and BMP4 genes.","date":"2007","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17696196","citation_count":47,"is_preprint":false},{"pmid":"15189984","id":"PMC_15189984","title":"SYM1 is the stress-induced Saccharomyces cerevisiae ortholog of the mammalian kidney disease gene Mpv17 and is required for ethanol metabolism and tolerance during heat shock.","date":"2004","source":"Eukaryotic cell","url":"https://pubmed.ncbi.nlm.nih.gov/15189984","citation_count":46,"is_preprint":false},{"pmid":"29456539","id":"PMC_29456539","title":"Generation of Human Immunosuppressive Myeloid Cell Populations in Human Interleukin-6 Transgenic NOG Mice.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29456539","citation_count":45,"is_preprint":false},{"pmid":"19182442","id":"PMC_19182442","title":"Higher susceptibility of NOG mice to xenotransplanted tumors.","date":"2009","source":"The Journal of toxicological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/19182442","citation_count":42,"is_preprint":false},{"pmid":"18097554","id":"PMC_18097554","title":"Liver metastasis models of colon cancer for evaluation of drug efficacy using NOD/Shi-scid IL2Rgammanull (NOG) mice.","date":"2008","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18097554","citation_count":42,"is_preprint":false},{"pmid":"24412093","id":"PMC_24412093","title":"Nestin delineates pancreatic cancer stem cells in metastatic foci of NOD/Shi-scid IL2Rγ(null) (NOG) mice.","date":"2014","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24412093","citation_count":40,"is_preprint":false},{"pmid":"22268628","id":"PMC_22268628","title":"In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-Hydroxythalidomide in humanized TK-NOG mice.","date":"2012","source":"Chemical research in toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/22268628","citation_count":40,"is_preprint":false},{"pmid":"31081549","id":"PMC_31081549","title":"Abscopal effect when combining oncolytic adenovirus and checkpoint inhibitor in a humanized NOG mouse model of melanoma.","date":"2019","source":"Journal of medical virology","url":"https://pubmed.ncbi.nlm.nih.gov/31081549","citation_count":39,"is_preprint":false},{"pmid":"25424997","id":"PMC_25424997","title":"Chimeric TK-NOG mice: a predictive model for cholestatic human liver toxicity.","date":"2014","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/25424997","citation_count":38,"is_preprint":false},{"pmid":"31839668","id":"PMC_31839668","title":"Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse.","date":"2019","source":"Biomedical research (Tokyo, Japan)","url":"https://pubmed.ncbi.nlm.nih.gov/31839668","citation_count":38,"is_preprint":false},{"pmid":"19032938","id":"PMC_19032938","title":"Reconstitution activity of hypoxic cultured human cord blood CD34-positive cells in NOG mice.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19032938","citation_count":38,"is_preprint":false},{"pmid":"23045398","id":"PMC_23045398","title":"The channel-forming Sym1 protein is transported by the TIM23 complex in a presequence-independent manner.","date":"2012","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23045398","citation_count":37,"is_preprint":false},{"pmid":"25077758","id":"PMC_25077758","title":"Characterization of EBV-related lymphoproliferative lesions arising in donor lymphocytes of transplanted human tumor tissues in the NOG mouse.","date":"2014","source":"Experimental animals","url":"https://pubmed.ncbi.nlm.nih.gov/25077758","citation_count":35,"is_preprint":false},{"pmid":"7557985","id":"PMC_7557985","title":"Localization of the gene (SYM1) for proximal symphalangism to human chromosome 17q21-q22.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7557985","citation_count":32,"is_preprint":false},{"pmid":"25996609","id":"PMC_25996609","title":"Spontaneous Post-Transplant Disorders in NOD.Cg- Prkdcscid Il2rgtm1Sug/JicTac (NOG) Mice Engrafted with Patient-Derived Metastatic Melanomas.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25996609","citation_count":32,"is_preprint":false},{"pmid":"1301398","id":"PMC_1301398","title":"Prolactin-induced protein kinase C activity in a mouse mammary cell line (NOG-8).","date":"1992","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/1301398","citation_count":31,"is_preprint":false},{"pmid":"24066957","id":"PMC_24066957","title":"Copper complexes relevant to the catalytic cycle of copper nitrite reductase: electrochemical detection of NO(g) evolution and flipping of NO2 binding mode upon Cu(II) → Cu(I) reduction.","date":"2013","source":"Inorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24066957","citation_count":30,"is_preprint":false},{"pmid":"1329946","id":"PMC_1329946","title":"Spectroscopic and redox properties of sym1 and (M)F195H: Rhodobacter capsulatus reaction center symmetry mutants which affect the initial electron donor.","date":"1992","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1329946","citation_count":29,"is_preprint":false},{"pmid":"34839181","id":"PMC_34839181","title":"An improved TK-NOG mouse as a novel platform for humanized liver that overcomes limitations in both male and female animals.","date":"2021","source":"Drug metabolism and pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/34839181","citation_count":29,"is_preprint":false},{"pmid":"11857750","id":"PMC_11857750","title":"Identification of a novel NOG gene mutation (P35S) in an Italian family with symphalangism.","date":"2002","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/11857750","citation_count":28,"is_preprint":false},{"pmid":"29387068","id":"PMC_29387068","title":"Enhanced Antibody Responses in a Novel NOG Transgenic Mouse with Restored Lymph Node Organogenesis.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29387068","citation_count":27,"is_preprint":false},{"pmid":"24066694","id":"PMC_24066694","title":"The human hepatic cell line HepaRG as a possible cell source for the generation of humanized liver TK-NOG mice.","date":"2013","source":"Xenobiotica; the fate of foreign compounds in biological systems","url":"https://pubmed.ncbi.nlm.nih.gov/24066694","citation_count":26,"is_preprint":false},{"pmid":"22288654","id":"PMC_22288654","title":"Mutations in the NOG gene are commonly found in congenital stapes ankylosis with symphalangism, but not in otosclerosis.","date":"2012","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22288654","citation_count":25,"is_preprint":false},{"pmid":"30850839","id":"PMC_30850839","title":"BLT-Immune Humanized Mice as a Model for Nivolumab-Induced Immune-Mediated Adverse Events: Comparison of the NOG and NOG-EXL Strains.","date":"2019","source":"Toxicological sciences : an official journal of the Society of Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/30850839","citation_count":25,"is_preprint":false},{"pmid":"12621334","id":"PMC_12621334","title":"Characterization of a stapes ankylosis family with a NOG mutation.","date":"2003","source":"Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology","url":"https://pubmed.ncbi.nlm.nih.gov/12621334","citation_count":24,"is_preprint":false},{"pmid":"17657714","id":"PMC_17657714","title":"Engraftment of peripheral blood mononuclear cells from human T-lymphotropic virus type 1 carriers in NOD/SCID/gammac(null) (NOG) mice.","date":"2007","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17657714","citation_count":23,"is_preprint":false},{"pmid":"16939817","id":"PMC_16939817","title":"Development of human-human hybridoma from anti-Her-2 peptide-producing B cells in immunized NOG mouse.","date":"2006","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/16939817","citation_count":22,"is_preprint":false},{"pmid":"24736495","id":"PMC_24736495","title":"Myo/Nog cells: targets for preventing the accumulation of skeletal muscle-like cells in the human lens.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24736495","citation_count":22,"is_preprint":false},{"pmid":"28055955","id":"PMC_28055955","title":"Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28055955","citation_count":21,"is_preprint":false},{"pmid":"27508084","id":"PMC_27508084","title":"A novel nonsense mutation in the NOG gene causes familial NOG-related symphalangism spectrum disorder.","date":"2016","source":"Human genome variation","url":"https://pubmed.ncbi.nlm.nih.gov/27508084","citation_count":21,"is_preprint":false},{"pmid":"18440889","id":"PMC_18440889","title":"P35S mutation in the NOG gene associated with Teunissen-Cremers syndrome and features of multiple NOG joint-fusion syndromes.","date":"2008","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18440889","citation_count":21,"is_preprint":false},{"pmid":"12404109","id":"PMC_12404109","title":"Evaluation of BMP4 and its specific inhibitor NOG as candidates in human neural tube defects (NTDs).","date":"2002","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/12404109","citation_count":21,"is_preprint":false},{"pmid":"25077762","id":"PMC_25077762","title":"NOD-Rag2null IL-2Rγnull mice: an alternative to NOG mice for generation of humanized mice.","date":"2014","source":"Experimental animals","url":"https://pubmed.ncbi.nlm.nih.gov/25077762","citation_count":20,"is_preprint":false},{"pmid":"15770128","id":"PMC_15770128","title":"The facio-audio-symphalangism syndrome in a four generation family with a nonsense mutation in the NOG-gene.","date":"2005","source":"Clinical dysmorphology","url":"https://pubmed.ncbi.nlm.nih.gov/15770128","citation_count":20,"is_preprint":false},{"pmid":"20696130","id":"PMC_20696130","title":"In vivo assay of human NK-dependent ADCC using NOD/SCID/gammac(null) (NOG) mice.","date":"2010","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/20696130","citation_count":20,"is_preprint":false},{"pmid":"21884693","id":"PMC_21884693","title":"Myo/Nog cell regulation of bone morphogenetic protein signaling in the blastocyst is essential for normal morphogenesis and striated muscle lineage specification.","date":"2011","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/21884693","citation_count":20,"is_preprint":false},{"pmid":"28617827","id":"PMC_28617827","title":"NOG-hIL-4-Tg, a new humanized mouse model for producing tumor antigen-specific IgG antibody by peptide vaccination.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28617827","citation_count":20,"is_preprint":false},{"pmid":"26246560","id":"PMC_26246560","title":"Human Cytotoxic T Lymphocyte-Mediated Acute Liver Failure and Rescue by Immunoglobulin in Human Hepatocyte Transplant TK-NOG Mice.","date":"2015","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/26246560","citation_count":19,"is_preprint":false},{"pmid":"25163482","id":"PMC_25163482","title":"The neutralizing function of the anti-HTLV-1 antibody is essential in preventing in vivo transmission of HTLV-1 to human T cells in NOD-SCID/γcnull (NOG) mice.","date":"2014","source":"Retrovirology","url":"https://pubmed.ncbi.nlm.nih.gov/25163482","citation_count":19,"is_preprint":false},{"pmid":"16077966","id":"PMC_16077966","title":"S100A4 expression with reduced E-cadherin expression predicts distant metastasis of human malignant melanoma cell lines in the NOD/SCID/gammaCnull (NOG) mouse model.","date":"2005","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/16077966","citation_count":19,"is_preprint":false},{"pmid":"24552710","id":"PMC_24552710","title":"Nucleolar GTPase NOG-1 regulates development, fat storage, and longevity through insulin/IGF signaling in C. elegans.","date":"2014","source":"Molecules and cells","url":"https://pubmed.ncbi.nlm.nih.gov/24552710","citation_count":18,"is_preprint":false},{"pmid":"28502122","id":"PMC_28502122","title":"Humanized NOG mice as a model for tuberculosis vaccine-induced immunity: a comparative analysis with the mouse and guinea pig models of tuberculosis.","date":"2017","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28502122","citation_count":17,"is_preprint":false},{"pmid":"32353144","id":"PMC_32353144","title":"RAD-seq-Based High-Density Linkage Map Construction and QTL Mapping of Biomass-Related Traits in Sorghum using the Japanese Landrace Takakibi NOG.","date":"2020","source":"Plant & cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32353144","citation_count":17,"is_preprint":false},{"pmid":"25391606","id":"PMC_25391606","title":"Identification of two novel mutations in the NOG gene associated with congenital stapes ankylosis and symphalangism.","date":"2014","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25391606","citation_count":16,"is_preprint":false},{"pmid":"30871027","id":"PMC_30871027","title":"HIV Replication in Humanized IL-3/GM-CSF-Transgenic NOG Mice.","date":"2019","source":"Pathogens (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/30871027","citation_count":16,"is_preprint":false},{"pmid":"22621191","id":"PMC_22621191","title":"Myo/Nog cells in normal, wounded and tumor-bearing skin.","date":"2012","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/22621191","citation_count":16,"is_preprint":false},{"pmid":"20503332","id":"PMC_20503332","title":"Facioaudiosymphalangism syndrome and growth acceleration associated with a heterozygous NOG mutation.","date":"2010","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/20503332","citation_count":16,"is_preprint":false},{"pmid":"19082472","id":"PMC_19082472","title":"Thrombospondin 2 inhibits metastasis of human malignant melanoma through microenvironment-modification in NOD/SCID/gammaCnull (NOG) mice.","date":"2009","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19082472","citation_count":16,"is_preprint":false},{"pmid":"38490714","id":"PMC_38490714","title":"Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice.","date":"2024","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38490714","citation_count":16,"is_preprint":false},{"pmid":"26688580","id":"PMC_26688580","title":"Neuroprotective effect of Myo/Nog cells in the stressed retina.","date":"2015","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/26688580","citation_count":15,"is_preprint":false},{"pmid":"31042787","id":"PMC_31042787","title":"Depletion of Myo/Nog Cells in the Lens Mitigates Posterior Capsule Opacification in Rabbits.","date":"2019","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/31042787","citation_count":15,"is_preprint":false},{"pmid":"21358557","id":"PMC_21358557","title":"Proximal symphalangism, hyperopia, conductive hearing impairment, and the NOG gene: 2 new mutations.","date":"2011","source":"Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology","url":"https://pubmed.ncbi.nlm.nih.gov/21358557","citation_count":15,"is_preprint":false},{"pmid":"29559302","id":"PMC_29559302","title":"Myo/Nog cells are present in the ciliary processes, on the zonule of Zinn and posterior capsule of the lens following cataract surgery.","date":"2018","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/29559302","citation_count":15,"is_preprint":false},{"pmid":"28099524","id":"PMC_28099524","title":"Role of Myo/Nog Cells in Neuroprotection: Evidence from the Light Damaged Retina.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28099524","citation_count":14,"is_preprint":false},{"pmid":"34311726","id":"PMC_34311726","title":"A defect in the NOG gene increases susceptibility to spontaneous superficial chronic corneal epithelial defects (SCCED) in boxer dogs.","date":"2021","source":"BMC veterinary research","url":"https://pubmed.ncbi.nlm.nih.gov/34311726","citation_count":14,"is_preprint":false},{"pmid":"32357972","id":"PMC_32357972","title":"Human Aldehyde Oxidase 1-Mediated Carbazeran Oxidation in Chimeric TK-NOG Mice Transplanted with Human Hepatocytes.","date":"2020","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/32357972","citation_count":14,"is_preprint":false},{"pmid":"16151340","id":"PMC_16151340","title":"Stapes ankylosis in a family with a novel NOG mutation: otologic features of the facioaudiosymphalangism syndrome.","date":"2005","source":"Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology","url":"https://pubmed.ncbi.nlm.nih.gov/16151340","citation_count":14,"is_preprint":false},{"pmid":"18481455","id":"PMC_18481455","title":"Antigen-specific antibody production of human B cells in NOG mice reconstituted with the human immune system.","date":"2008","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18481455","citation_count":14,"is_preprint":false},{"pmid":"33455497","id":"PMC_33455497","title":"Methyl-hydroxylation and subsequent oxidation to produce carboxylic acid is the major metabolic pathway of tolbutamide in chimeric TK-NOG mice transplanted with human hepatocytes.","date":"2021","source":"Xenobiotica; the fate of foreign compounds in biological systems","url":"https://pubmed.ncbi.nlm.nih.gov/33455497","citation_count":13,"is_preprint":false},{"pmid":"26211601","id":"PMC_26211601","title":"Novel NOG mutation in Japanese patients with stapes ankylosis with broad thumbs and toes.","date":"2015","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26211601","citation_count":13,"is_preprint":false},{"pmid":"38197423","id":"PMC_38197423","title":"Humanization with CD34-positive hematopoietic stem cells in NOG-EXL mice results in improved long-term survival and less severe myeloid cell hyperactivation phenotype relative to NSG-SGM3 mice.","date":"2024","source":"Veterinary pathology","url":"https://pubmed.ncbi.nlm.nih.gov/38197423","citation_count":13,"is_preprint":false},{"pmid":"33117338","id":"PMC_33117338","title":"Improved Detection of in vivo Human NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity Using a Novel NOG-FcγR-Deficient Human IL-15 Transgenic Mouse.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33117338","citation_count":13,"is_preprint":false},{"pmid":"31690163","id":"PMC_31690163","title":"Metabolism of desloratadine by chimeric TK-NOG mice transplanted with human hepatocytes.","date":"2019","source":"Xenobiotica; the fate of foreign compounds in biological systems","url":"https://pubmed.ncbi.nlm.nih.gov/31690163","citation_count":12,"is_preprint":false},{"pmid":"30273399","id":"PMC_30273399","title":"Pathological alleles of MPV17 modeled in the yeast Saccharomyces cerevisiae orthologous gene SYM1 reveal their inability to take part in a high molecular weight complex.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30273399","citation_count":12,"is_preprint":false},{"pmid":"25241334","id":"PMC_25241334","title":"Variable phenotypes of multiple synostosis syndrome in patients with novel NOG mutations.","date":"2014","source":"Joint bone spine","url":"https://pubmed.ncbi.nlm.nih.gov/25241334","citation_count":12,"is_preprint":false},{"pmid":"19167531","id":"PMC_19167531","title":"Identification and association analysis of single nucleotide polymorphisms in the human noggin (NOG) gene and osteoporosis phenotypes.","date":"2009","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/19167531","citation_count":12,"is_preprint":false},{"pmid":"19923914","id":"PMC_19923914","title":"C. elegans sym-1 is a downstream target of the hunchback-like-1 developmental timing transcription factor.","date":"2009","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/19923914","citation_count":12,"is_preprint":false},{"pmid":"18946184","id":"PMC_18946184","title":"Establishing EGFP congenic mice in a NOD/Shi-scid IL2Rg(null) (NOG) genetic background using a marker-assisted selection protocol (MASP).","date":"2008","source":"Experimental animals","url":"https://pubmed.ncbi.nlm.nih.gov/18946184","citation_count":11,"is_preprint":false},{"pmid":"17994231","id":"PMC_17994231","title":"Cushing proximal symphalangism and the NOG and GDF5 genes.","date":"2007","source":"Pediatric radiology","url":"https://pubmed.ncbi.nlm.nih.gov/17994231","citation_count":10,"is_preprint":false},{"pmid":"29476044","id":"PMC_29476044","title":"Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice.","date":"2018","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/29476044","citation_count":10,"is_preprint":false},{"pmid":"32614850","id":"PMC_32614850","title":"Brain-specific angiogenesis inhibitor 1 is expressed in the Myo/Nog cell lineage.","date":"2020","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/32614850","citation_count":10,"is_preprint":false},{"pmid":"17889703","id":"PMC_17889703","title":"Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis.","date":"2007","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/17889703","citation_count":9,"is_preprint":false},{"pmid":"36002046","id":"PMC_36002046","title":"HIF-1α drives the transcription of NOG to inhibit osteogenic differentiation of periodontal ligament stem cells in response to hypoxia.","date":"2022","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/36002046","citation_count":9,"is_preprint":false},{"pmid":"19400542","id":"PMC_19400542","title":"Mutations of the noggin (NOG) and of the activin A type I receptor (ACVR1) genes in a series of twenty-seven French fibrodysplasia ossificans progressiva (FOP) patients.","date":"2009","source":"Genetic counseling (Geneva, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/19400542","citation_count":9,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49388,"output_tokens":2527,"usd":0.093035},"stage2":{"model":"claude-opus-4-6","input_tokens":5853,"output_tokens":2520,"usd":0.138398},"total_usd":0.231433,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"Disease-causing NOG missense mutations (one SYNS1 and two SYM1) reduce or abolish secretion of functional noggin dimers in transiently transfected COS-7 cells; coexpression of mutant with wild-type noggin does not interfere with wild-type secretion, indicating hypomorphic alleles that reduce functional dimeric noggin secretion. Species-specific differences were also noted: the SYNS1 mutant could still form dimers in Xenopus laevis oocytes but not in COS-7 cells.\",\n      \"method\": \"Transient transfection in COS-7 cells, dimer formation assay, BMP binding assay, Xenopus oocyte expression\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro functional assay with multiple mutant alleles, BMP-binding and dimerization readouts, cross-species validation\",\n      \"pmids\": [\"11562478\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Heterozygous nonsense (Q110X) and frameshift (c.252-253insC) NOG mutations predicted to truncate or disrupt the cysteine-rich C-terminal domain cause a congenital stapes ankylosis syndrome distinct from SYM1/SYNS1, establishing that the C-terminal cysteine-rich domain is critical for noggin function and that different truncating mutations produce different skeletal phenotypes.\",\n      \"method\": \"Sequencing of NOG in affected families; genotype-phenotype correlation\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — genetic identification of loss-of-function alleles with clear functional inference about domain requirement, but no direct in vitro functional assay\",\n      \"pmids\": [\"12089654\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Identical NOG missense mutations (e.g., those originally described in SYM1) can also cause tarsal/carpal coalition syndrome (TCC), demonstrating that the same NOG allele can produce different skeletal fusion phenotypes, implying epistatic modifiers act on the NOG pathway.\",\n      \"method\": \"Genetic sequencing of NOG in three kindreds with TCC; comparison with known SYM1 mutations\",\n      \"journal\": \"Genetics in medicine : official journal of the American College of Medical Genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 + Strong — replicated across multiple families and cross-referenced to prior SYM1 mutations, establishing pathway epistasis context\",\n      \"pmids\": [\"11545688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NOG (noggin, a BMP inhibitor) expression is selectively acquired by breast cancer cells during bone metastasis (not enriched in primary tumors). Using genetic knockdown/overexpression, NOG was shown to facilitate bone colonization by fostering osteoclast differentiation and bone degradation, and to contribute to metastatic lesion reinitiation, coupling cancer cell-autonomous and nonautonomous (osteoclast-mediated) functions.\",\n      \"method\": \"Genetic knockdown and overexpression in human breast cancer cells; in vivo bone metastasis assay; osteoclast differentiation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic loss-of-function and gain-of-function with defined cellular and in vivo phenotypes (osteoclast differentiation, bone colonization)\",\n      \"pmids\": [\"22547073\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HIF-1α directly binds to a hypoxia response element (HRE at -1505 to -1502) in the NOG promoter to transcriptionally upregulate NOG/Noggin expression under hypoxia, resulting in inhibition of osteogenic differentiation of periodontal ligament stem cells (PDLSCs). Overexpression of HIF-1α increased Noggin levels and suppressed osteogenesis-related gene expression; HIF-1α inhibition reversed these effects.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), dual-luciferase reporter assay, qRT-PCR, Western blot, HIF-1α overexpression/inhibition in PDLSCs, in vivo animal model IHC\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP and luciferase reporter directly demonstrate HIF-1α binding to NOG promoter HRE; supported by gain/loss-of-function experiments and in vivo validation\",\n      \"pmids\": [\"36002046\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Myo/Nog cells in the chick embryo express both MyoD mRNA and the BMP inhibitor Noggin (Nog). Ablation of Myo/Nog cells in the blastocyst expands canonical BMP signaling, prevents noggin and follistatin expression before and after gastrulation, and causes severe axial malformations with loss of skeletal muscle progenitors (Pax3+); reintroduction of Myo/Nog cells restores normal BMP signaling, morphogenesis, and skeletal myogenesis. This identifies Myo/Nog cells as essential regulators of BMP signaling in the early epiblast through Noggin secretion.\",\n      \"method\": \"Cell ablation in chick blastocyst using G8 mAb + complement; reintroduction rescue experiments; immunofluorescence for BMP pathway components and myogenic markers\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ablation with rescue, multiple orthogonal readouts (BMP signaling, Pax3 expression, myogenesis markers), establishes NOG's role in BMP inhibition in developmental context\",\n      \"pmids\": [\"21884693\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Myo/Nog cells are the primary source of noggin in telogen hair follicles and in anterior lens tissue. Depletion of Myo/Nog cells from human lens explants eliminated cells expressing skeletal muscle proteins (including vimentin, MyoD, sarcomeric myosin) without affecting differentiating lens epithelial cells, and prevented TGF-β-induced skeletal muscle protein expression, demonstrating that Myo/Nog cells are the source of myofibroblast precursors in the lens and that Noggin from these cells modulates BMP signaling in lens tissue.\",\n      \"method\": \"G8 antibody-mediated depletion of Myo/Nog cells from human lens explants; immunofluorescence; TGF-β stimulation assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — depletion experiment with clear phenotypic readout in human tissue; single lab\",\n      \"pmids\": [\"24736495\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A 30 bp deletion at a splice site in the NOG gene in Boxer dogs is significantly associated with spontaneous superficial chronic corneal epithelial defects (SCCEDs). NOG deletion dogs showed reduced NOG, BMP4, MMP13, and NCAM1 expression and increased BMP2 by IHC, indicating that constitutive NOG expression in the cornea inhibits BMP signaling to regulate limbal epithelial progenitor cells (LEPC), and loss of NOG dysregulates LEPC, contributing to corneal epithelial defects.\",\n      \"method\": \"Whole genome sequencing; RNA sequencing of corneal tissue; immunohistochemistry of corneal sections\",\n      \"journal\": \"BMC veterinary research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — natural loss-of-function model with transcriptomic and IHC validation; functional link to BMP pathway supported by multi-gene expression data\",\n      \"pmids\": [\"34311726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"A common variant (rs227727) near NOG disrupts enhancer activity in vitro, and a significant cluster of non-coding rare variants near NOG were identified in orofacial cleft patients, suggesting that cis-regulatory elements controlling NOG expression are functional contributors to cleft risk.\",\n      \"method\": \"Targeted sequencing in 1,409 trios; enhancer activity assay in vitro\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — functional enhancer assay with statistical genetic support; limited to one in vitro readout for NOG-specific variant\",\n      \"pmids\": [\"25704602\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NOG encodes Noggin, a secreted BMP antagonist that forms functional dimers via its cysteine-rich C-terminal domain; disease-causing missense mutations reduce or abolish functional dimer secretion (hypomorphic alleles), while truncating mutations in the C-terminal domain produce distinct skeletal fusion phenotypes. Noggin inhibits BMP signaling in skeletal and epithelial development (regulating joint formation, bone remodeling, and limbal progenitor maintenance), is transcriptionally upregulated by HIF-1α binding directly to a promoter HRE under hypoxia, and in cancer facilitates bone metastasis colonization by promoting osteoclast differentiation and bone degradation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"NOG encodes Noggin, a secreted BMP antagonist that functions as a disulfide-linked homodimer through its cysteine-rich C-terminal domain to inhibit BMP signaling during skeletal, epithelial, and axial development [PMID:11562478, PMID:21884693]. Noggin secretion by specialized Myo/Nog cells is essential for restraining canonical BMP signaling in the early epiblast, hair follicles, lens tissue, and corneal limbal epithelium, where it maintains progenitor cell populations and regulates osteogenic and myogenic differentiation [PMID:21884693, PMID:24736495, PMID:34311726]. Heterozygous loss-of-function mutations in NOG—including missense alleles that abolish functional dimer secretion and truncating mutations disrupting the C-terminal domain—cause a spectrum of skeletal fusion disorders including proximal symphalangism, multiple synostoses syndrome, stapes ankylosis, and tarsal/carpal coalition syndrome, with phenotypic variability implicating epistatic modifiers [PMID:11562478, PMID:12089654, PMID:11545688]. NOG transcription is directly upregulated by HIF-1α binding to a promoter hypoxia response element, and aberrant NOG expression by metastatic breast cancer cells promotes bone colonization by driving osteoclast differentiation and bone degradation [PMID:36002046, PMID:22547073].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Establishing how disease-causing NOG mutations impair protein function resolved the molecular basis of symphalangism/synostosis: missense alleles are hypomorphic because they reduce or abolish secretion of functional noggin dimers without dominant-negative interference with wild-type protein.\",\n      \"evidence\": \"Transient transfection of mutant and wild-type NOG in COS-7 cells with dimer formation and BMP-binding assays; cross-species validation in Xenopus oocytes\",\n      \"pmids\": [\"11562478\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Crystal structure of mutant dimers was not resolved\",\n        \"Cell-type specificity of dimerization failure (COS-7 vs. Xenopus) was unexplained mechanistically\",\n        \"No in vivo rescue of skeletal phenotype attempted\"\n      ]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrating that identical NOG missense mutations produce distinct skeletal fusion phenotypes (SYM1 vs. tarsal/carpal coalition) established that epistatic modifiers act on the NOG/BMP pathway to determine phenotypic outcome.\",\n      \"evidence\": \"Genetic sequencing of NOG in three TCC kindreds identifying previously reported SYM1 mutations\",\n      \"pmids\": [\"11545688\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Identity of epistatic modifier loci was not determined\",\n        \"No functional assay performed for the TCC-associated alleles in this study\"\n      ]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identifying truncating NOG mutations (Q110X and frameshift) that disrupt the cysteine-rich C-terminal domain in a stapes ankylosis phenotype distinct from SYM1/SYNS1 established that the C-terminal domain is essential for noggin function and that allelic heterogeneity at NOG produces a broad phenotypic spectrum.\",\n      \"evidence\": \"Sequencing of NOG in affected families with congenital stapes ankylosis; genotype-phenotype correlation\",\n      \"pmids\": [\"12089654\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No direct biochemical assay of truncated protein function\",\n        \"Mechanism by which partial C-terminal loss produces stapes-specific ankylosis rather than generalized synostosis was not explained\"\n      ]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showing that breast cancer cells selectively acquire NOG expression during bone metastasis and that NOG promotes osteoclast differentiation and bone colonization revealed a non-developmental, pathological role for Noggin's BMP-antagonist activity in the metastatic niche.\",\n      \"evidence\": \"Genetic knockdown and overexpression in human breast cancer cells; in vivo bone metastasis and osteoclast differentiation assays\",\n      \"pmids\": [\"22547073\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Which specific BMPs are antagonized in the bone metastatic niche was not identified\",\n        \"Whether NOG's pro-metastatic role extends beyond breast cancer was not tested\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Ablation and rescue of Myo/Nog cells in chick embryos demonstrated that these cells are essential sources of Noggin that restrain BMP signaling in the epiblast, and that loss of Noggin causes severe axial malformations and loss of skeletal muscle progenitors.\",\n      \"evidence\": \"G8 mAb + complement-mediated cell ablation in chick blastocyst with reintroduction rescue; immunofluorescence for BMP pathway and myogenic markers\",\n      \"pmids\": [\"21884693\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Relative contribution of Noggin versus Follistatin from Myo/Nog cells was not separated\",\n        \"Mammalian equivalence of the Myo/Nog cell population was not demonstrated\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Depletion of Myo/Nog cells from human lens explants identified these cells as the primary Noggin source in lens tissue and as the precursors of TGF-β-induced myofibroblasts, connecting Noggin-mediated BMP inhibition to lens epithelial homeostasis.\",\n      \"evidence\": \"G8 antibody-mediated depletion from human lens explants; immunofluorescence; TGF-β stimulation\",\n      \"pmids\": [\"24736495\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single-lab finding not independently replicated\",\n        \"Direct measurement of secreted Noggin levels after depletion was not reported\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identifying a common variant near NOG that disrupts enhancer activity and rare non-coding variant clusters in orofacial cleft patients established that cis-regulatory control of NOG expression contributes to craniofacial morphogenesis.\",\n      \"evidence\": \"Targeted sequencing in 1,409 trios; in vitro enhancer activity assay\",\n      \"pmids\": [\"25704602\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Only one variant tested functionally; remaining rare variants lack individual functional validation\",\n        \"In vivo enhancer activity not confirmed\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"A natural NOG loss-of-function model in dogs showed that constitutive corneal NOG expression inhibits BMP signaling to maintain limbal epithelial progenitor cells, and its loss dysregulates BMP2/BMP4 balance leading to chronic corneal defects.\",\n      \"evidence\": \"Whole genome sequencing and RNA-seq of corneal tissue in Boxer dogs with 30 bp NOG deletion; IHC validation\",\n      \"pmids\": [\"34311726\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Causal rescue experiment not performed\",\n        \"Whether NOG loss directly or indirectly alters limbal progenitor self-renewal was not resolved\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrating that HIF-1α directly binds a hypoxia response element in the NOG promoter to upregulate transcription identified the first direct transcriptional regulator of NOG and linked hypoxia signaling to suppression of osteogenic differentiation via the NOG/BMP axis.\",\n      \"evidence\": \"ChIP, dual-luciferase reporter assay, HIF-1α overexpression/inhibition in PDLSCs, in vivo IHC\",\n      \"pmids\": [\"36002046\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether HIF-1α regulation of NOG operates in tissues beyond periodontal ligament was not tested\",\n        \"Additional transcription factors controlling NOG in skeletal development remain unidentified\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis of Noggin dimerization-dependent BMP sequestration at atomic resolution, the full repertoire of transcriptional regulators driving tissue-specific NOG expression, and the identity of epistatic modifiers that determine phenotypic outcome of NOG mutations remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No high-resolution structure of disease-associated Noggin mutant dimers\",\n        \"Epistatic modifier loci for NOG-related skeletal phenotypes not mapped\",\n        \"Comprehensive cis-regulatory map of the NOG locus across tissues not established\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 3, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 3, 5, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 3, 5, 7]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1, 2, 5, 8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"HIF1A\",\n      \"BMP2\",\n      \"BMP4\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}